Introduction
============

Ischemia/reperfusion (I/R) causes severe damage to vital organs, including the brain, heart, lungs and kidneys ([@b1-etm-0-0-6457]--[@b4-etm-0-0-6457]). I/R injury encompasses stroke, which is characterized by a sudden focal or global neurological impairment and is one of the most prevalent causes of mortality and disability worldwide ([@b5-etm-0-0-6457]--[@b7-etm-0-0-6457]).

In principle, cerebral ischemia is caused by cerebral blood flow reduction leading to a series of pathological changes, including ionic homeostasis loss, energy failure, increased oxidative stress, apoptosis, irreversible tissue/organ damage and neurological and behavioral deficits ([@b8-etm-0-0-6457],[@b9-etm-0-0-6457]). I/R injury-induced damage is associated with dysregulation of complex interactions, inflammatory responses and extracellular matrix (ECM) remodeling ([@b10-etm-0-0-6457]). The ECM forms a key component of the basement membrane, and is essential for the permeability and integrity of blood-brain barrier (BBB), while matrix metalloproteinases (MMPs) can exert proteolytic activity to degrade all ECM components ([@b1-etm-0-0-6457],[@b11-etm-0-0-6457]).

Abnormal degradation of ECM components in rats with cerebral I/R injury reduces the integrity and permeability of the BBB, which may lead to leakage of fluids from the blood to the brain and subsequent brain edema ([@b1-etm-0-0-6457]). Type IV collagen is a key component of the ECM complex and a major proteolytic substrate of MMP2 and MMP9 ([@b1-etm-0-0-6457]). Overexpression of MMP2 and MMP9 has previously been reported in I/R injured tissues, including the heart, liver and kidneys ([@b1-etm-0-0-6457],[@b3-etm-0-0-6457],[@b12-etm-0-0-6457]). Furthermore, breakdown of the BBB in rats may be induced by upregulated proteolytic activity of MMP2 and MMP9, which subsequently results in over-degradation of type IV collagen to reduce BBB integrity and promote BBB permeability ([@b1-etm-0-0-6457]).

At present, typical pharmacological agents used to treat cerebral I/R injury therapy are neuroprotective, antioxidative, antiapoptotic or anti-inflammatory agents ([@b13-etm-0-0-6457],[@b14-etm-0-0-6457]). Previous studies have reported the protective effect of morroniside, an active extract of *Cornus officinalis*, against neuronal apoptosis, oxidative stress and inflammation ([@b8-etm-0-0-6457],[@b15-etm-0-0-6457]--[@b17-etm-0-0-6457]). Furthermore, the neuroprotective effect of morroniside has been reported in rats with focal cerebral ischemia ([@b8-etm-0-0-6457]). However, to the best of our knowledge, the effect of morroniside on MMP2/9 expression and neuron apoptosis in cerebral I/R injury has yet to be reported.

The aim of the present study was to elucidate the effect of morroniside on MMP2/9 expression and neuron apoptosis in rats with cerebral I/R injury. Rats with focal cerebral I/R injury were administrated with morroniside (30, 90 and 270 mg/kg) for 7 days, following which MMP2/9 expression and neuronal apoptosis were detected and comparatively analyzed.

Materials and methods
=====================

### Animal model and treatment

A total of 50 adult male Sprague Dawley rats (age, 7--8 weeks; weight, 260--280 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All rats were housed at 25±2°C and 50% humidity, with a 12-h light/dark cycle, and food and water *ad libitum*. Ethical approval was granted by the Medical Ethics Committee of the Affiliated Ganzhou Hospital of Nanchang University (Nanchang, China).

Rats were randomly assigned into five groups (n=10 in each). Rats in the control group underwent sham surgery. All other rats underwent suture-occluded surgery as described by Longa *et al* ([@b18-etm-0-0-6457]), with a 0.26 mm nylon monofilament (Beijing Shandong Biotech Co., Ltd., Beijing, China) inserted through the right common carotid artery and were divided into groups as follows: The cerebral I/R injury model group (model), no treatment; low dose group, 30 mg/kg/day morroniside (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) by gavage; moderate dose group, 90 mg/kg/day morroniside by gavage; high dose group, 270 mg/kg/day morroniside by gavage. Rats in the control and model groups received an equal volume of normal saline. Longa\'s five-grade scale methods were used to score neurological deficit following surgery ([@b18-etm-0-0-6457]) and rats with a score of 0 or 4 were excluded from the current study.

### Immunofluorescence assay

Following 7 days of morroniside treatment, rats were anesthetized intravenously (30 mg/kg 5% pentobarbital sodium; Sigma Aldrich; Merck KGaA, Darmstadt, Germany) and brains were harvested. Brain tissues were mounted in optimal cutting temperature medium (Sakura Finetek USA, Inc., Torrance, CA, USA), frozen at −20°C in a Leica cryostat device (Leica Microsystems GmbH, Wetzlar, Germany) and cut into 4-µm sections. Sections were treated with 3% H~2~O~2~ solutions for 20 min at 37°C, blocked with normal goat serum (Sigma Aldrich; Merck KGaA) for 30 min at 37°C, and incubated with anti-MMP2 (cat. no. sc-13594) and anti-MMP9 (cat. no. sc-21733; 1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies at 4°C for 20 h. Sections were subsequently incubated with Cy3^®^-labelled goat anti-mouse immunoglobulin (Ig)G (cat. no. ab97035; 1:100; Abcam, Cambridge, MA, USA) in the dark at 37°C for 2 h. DAPI solution was used for nuclear staining at 37°C for 10 min. Slides were observed using a fluorescence microscope (magnification, ×200) and assessed using Image-Pro Plus 6 software (Media Cybernetics, Inc., Rockville, MD USA).

### Apoptotic cell analysis

Apoptotic cells in brain tissues were detected using a TUNEL assay. Briefly, ischemic penumbra cortex area was resected and the frozen sections (4-µm-thick) were fixed using 4% polyoxymethylene at room temperature for 20 min. and and a colorimetric TUNEL kit (EMD Millipore, Billerica, MA, USA) was used according to the manufacturer\'s protocol for *in situ* apoptosis detection. The sections were washed by PBS and then incubated with prepared TUNEL solution for 1 h at 37°C in a dark chamber. A 50 µl DAB solution (2.5 µl DAB, 0.5 µl 30% H~2~O~2~ and 47 µl PBS) was added for nuclear staining at 37°C for 20 min. The TUNEL-positive cells were observed and counted under a light microscope at a magnification of ×200. Apoptotic cells were stained brown and the mean was calculated from 10 independent fields.

### Western blotting

Brain tissues were homogenized and lysed in radioimmunoprecipitation assay buffer (Sigma Aldrich; Merck KGaA). Proteins were quantified using BCA method and equal amounts (50 µg) were separated by 8% SDS-PAGE. Proteins were transferred to a polyvinylidene fluoride membrane, blocked with 5% non-fat milk at 37°C for 1 h, and then was subsequently incubated with specific primary antibodies against MMP2 (cat. no. sc-13594), MMP9 (cat. no. sc-21733), active Caspase-3 (cat. no. sc-56052), B-cell lymphoma 2 (Bcl-2; cat. no. sc-56015) and Bcl-2-associated X protein (Bax; cat. no. sc-70407) and GAPDH (cat. no. sc-47724; all 1:1,000; Santa Cruz Biotechnology, Inc.) at 4°C overnight. The membrane was incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (cat. no. sc-2004; 1:1,000, Santa Cruz Biotechnology, Inc.) for 2 h at 37°C followed by enhanced chemilluminescence reagents (GE Healthcare Life Sciences, Little Chalfont, UK). Quantity One 4.4.1 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to quantify bands with GAPDH as an internal control.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

RT-qPCR was performed to measure the relative expression of MMP2 and MMP9 mRNA. Total RNA was extracted from brain tissues using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and RT was performed to synthesize cDNA. RNA was converted into cDNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. MMP2 and MMP9 mRNA expression was detected on an ABI 7500 fast real time PCR platform (Applied Biosystems; Thermo Fisher Scientific, Inc.) using a SYBR Premix Ex Taq™ kit (Takara Bio, Inc., Otsu, Japan) and the following primers: MMP2, forward 5′-CTGGGCCACGCCATCGCTGC-3 and reverse 5′-GCTTGCGGGGAAAGAAGTTG-3′; MMP9, forward 5′-GGCAGCCCCTGCTCCTGGTG-3′ and reverse 5′-CCTTTAGTGTCTCGCTGTCC-3′; GAPDH, forward 5′-CTCCTCCTGGCCTCGCTGT-3′ and reverse 5′-GCTGTCACCTTCACCGTTCC-3′. Temperature protocols were as follows: 95°C for 4 min followed by 40 cycles of 95°C for 30 sec, 60°C for 35 sec and 72°C for 20 sec and a final extension step at 65°C for 6 min. The relative mRNA expression level was analyzed using the 2^−∆∆Cq^ method with GAPDH as the internal reference gene ([@b19-etm-0-0-6457]). Each reaction was run in triplicate.

### Statistical analysis

All data are expressed as the mean ± standard error of the mean. SPSS 17.0 software was used for statistical analyses (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance followed by Scheffe\'s test was used to assess differences between groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Morroniside reduces the expression of MMP2 and MMP9 in an I/R injury model

The results of western blotting and RT-qPCR revealed that MMP2 and MMP9 protein ([Fig. 1A](#f1-etm-0-0-6457){ref-type="fig"}) and mRNA (P\<0.01; [Fig. 1B](#f1-etm-0-0-6457){ref-type="fig"}) expression was increased in the model group compared with the control group. However, treatment with morroniside reduced the expression of MMP2 and MMP9 mRNA ([Fig. 1A](#f1-etm-0-0-6457){ref-type="fig"}) and protein (low dose, P\<0.05; moderate and high doses, P\<0.01; [Fig. 1B](#f1-etm-0-0-6457){ref-type="fig"}) in a dose dependent manner compared with the model group. Immunofluorescence results revealed that the pattern of MMP2 and MMP9 positive cells in cortical infarctions followed a similar trend to protein expression ([Fig. 2](#f2-etm-0-0-6457){ref-type="fig"}). The MMP2 and MMP9 fluorescence intensity in the brains of rats was increased in the model group compared with the control ([Fig. 2](#f2-etm-0-0-6457){ref-type="fig"}). However, treatment with morroniside markedly reduced MMP2 and MMP9 fluorescence compared with the model group ([Fig. 2](#f2-etm-0-0-6457){ref-type="fig"}).

### Morroniside inhibits neuron apoptosis

Apoptotic neurons on the sections from ischemic penumbra cortex were detected using a TUNEL assay. The percentage of apoptotic neurons was significantly increased in the model group compared with the control (P\<0.01; [Fig. 3A](#f3-etm-0-0-6457){ref-type="fig"}). However, treatment with morroniside significantly reduced I/R-associated neuron apoptosis in a dose dependent manner (low and moderate doses, P\<0.05; high dose, P\<0.01; [Fig. 3A](#f3-etm-0-0-6457){ref-type="fig"}). The expression of apoptosis-associated proteins was assessed using western blotting. The results demonstrated that active caspase-3 and Bax were significantly upregulated in the model group compared with the control group (P\<0.01; [Fig. 3B](#f3-etm-0-0-6457){ref-type="fig"}), while Bcl-2 was significantly downregulated (P\<0.01; [Fig. 3B](#f3-etm-0-0-6457){ref-type="fig"}). The expression of active caspase-3 and Bax was significantly downregulated by morroniside treatment in a dose-dependent manner (low dose, P\<0.05; moderate and high doses, P\<0.01; [Fig. 3B](#f3-etm-0-0-6457){ref-type="fig"}), while the expression of Bcl-2 was significantly upregulated (low dose, P\<0.05; moderate and high doses, P\<0.01; [Fig. 3B](#f3-etm-0-0-6457){ref-type="fig"}).

Discussion
==========

The upregulation of MMPs, in particular MMP2 and MMP9, results in the degradation of type IV collagen, which in turn impairs BBB integrity and enhances I/R injuries in the brain ([@b1-etm-0-0-6457]). The present study is the first to demonstrate the effect of morroniside treatment on MMP2/9 expression and neuron apoptosis and in I/R. The results revealed that MMP2 and MMP9 are upregulated in the brains of rats with cerebral I/R injury, whereas the administration of morroniside significantly ameliorated this effect. These results suggest that morroniside may convey a protective effect in the brains of rats with I/R injury.

Increased MMP2 and MMP9 expression has been reported in I/R injuries of the lung, heart, skeletal muscle, kidneys and other organs ([@b1-etm-0-0-6457]--[@b4-etm-0-0-6457]). Previous studies have revealed that MMP2/9 overexpression disrupts the BBB and results in edema ([@b20-etm-0-0-6457],[@b21-etm-0-0-6457]). It has also been reported that the inhibition of MMP2/9 may protect against cerebral ischemia and improve organ function ([@b12-etm-0-0-6457],[@b22-etm-0-0-6457]--[@b25-etm-0-0-6457]). However, MMP2 knockout does not protect against acute focal ischemia injury in brain ([@b26-etm-0-0-6457]). Kato *et al* ([@b10-etm-0-0-6457]) demonstrated that MMP2 deletion was able to impair poly ADP-ribose polymerase 1 degradation, enhance MMP9 activity and exacerbate hepatic I/R injury in mice ([@b10-etm-0-0-6457]). It has also been reported that whereas MMP9 deficiency may protect against hepatic I/R injury ([@b12-etm-0-0-6457]). Together, these reports suggest that effect of MMP2/9 in I/R injury is complex and, while MMP2/9 inhibition may be beneficial, it is not necessarily required to improve I/R injury. However, the results of the present study demonstrated that morroniside administration inhibits MMP2 and MMP9 in I/R injured brains, revealing morroniside was beneficial to protect against cerebral I/R injury.

The results of the present study revealed that morroniside significantly reduces the percentage of apoptotic neurons, inhibits caspase-3 activation and increases the Bcl-2/Bax protein ratio in rats with cerebral I/R injury. Cerebral I/R injury results in neurological and behavioral deficits, which are accompanied by neuron apoptosis ([@b9-etm-0-0-6457],[@b27-etm-0-0-6457],[@b28-etm-0-0-6457]). Wang *et al* ([@b16-etm-0-0-6457]) reported that morroniside was able to reduce H~2~O~2~-induced SH-SY5Y cell apoptosis, intracellular Ca^2+^ accumulation and mitochondrial membrane potential, while also inhibiting the H~2~O~2~-induced decrease in superoxide dismutase activity ([@b16-etm-0-0-6457]). The protective effect of morroniside on cell apoptosis and other diseases has been widely reported ([@b8-etm-0-0-6457],[@b29-etm-0-0-6457],[@b30-etm-0-0-6457]). The results of the present study suggest that morroniside treatment has a protective effect against I/R-induced neuron apoptosis; future studies should investigate the effect of MMP2 or MMP9 in rats with I/R injury to confirm the mechanisms of morroniside.

In conclusion, the present study revealed that protective effect of morroniside in rats with cerebral I/R injury. Morroniside inhibits the I/R-induced upregulation of MMP2/9 and neuron apoptosis, suggesting that morroniside may promote behavioral deficit repair following cerebral I/R injury. However, the underlying mechanism responsible for these effects remains to be elucidated.
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![Western blotting and reverse transcription-quantitative polymerase chain reaction were performed to measure MMP2 and MMP9 (A) protein and (B) mRNA, respectively, in rat brain tissues (n=10). \*\*P\<0.01 vs. Con, ^&^P\<0.05 an ^&&^P\<0.01 vs. Model. MMP, matrix metalloproteinase; Con, control; Low, 30 mg/kg morroniside; Mod, 90 mg/kg morroniside; High, 270 mg/kg morroniside.](etm-16-03-2229-g00){#f1-etm-0-0-6457}

![An immunofluorescence assay was performed to assess the expression of (A) MMP2 and (B) MMP9 in rat brain tissues (n=10). Magnification, ×200. MMP, matrix metalloproteinase; Con, control; Low, 30 mg/kg morroniside; Mod, 90 mg/kg morroniside; High, 270 mg/kg morroniside.](etm-16-03-2229-g01){#f2-etm-0-0-6457}

![(A) A TUNEL assay was performed to quantify apoptotic neurons in a cerebral ischemia/reperfusion injury model (n=10 rats). (B) Western blotting was performed to measure the expression of active caspase-3, Bcl-2 and Bax protein. Magnification, ×200. \*\*P\<0.01 vs. Con, ^&^P\<0.05 an ^&&^P\<0.01 vs. Model. Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; Con, control; Low, 30 mg/kg morroniside; Mod, 90 mg/kg morroniside; High, 270 mg/kg morroniside.](etm-16-03-2229-g02){#f3-etm-0-0-6457}
